Panizo Nayara, Rubio-Navarro Alfonso, Amaro-Villalobos Juan Manuel, Egido Jesús, Moreno Juan Antonio
Nefrovall, B-BRAUN Avitum. La Vall d' Uixx00F3;, Castellx00F3;n, Spain.
Kidney Blood Press Res. 2015;40(5):520-32. doi: 10.1159/000368528. Epub 2015 Oct 20.
Rhabdomyolysis is a syndrome caused by injury to skeletal muscle that usually leads to acute kidney injury (AKI). Rhabdomyolysis has been linked to different conditions, including severe trauma and intense physical exercise. Myoglobin-induced renal toxicity plays a key role in rhabdomyolysis-associated kidney damage by increasing oxidative stress, inflammation, endothelial dysfunction, vasoconstriction, and apoptosis. New drugs that target the harmful effects of myoglobin have been recently developed, and some have been proven to be successful in animal models of acute renal failure secondary to rhabdomyolysis. This review aims to provide a comprehensive and updated overview of the pathological mechanisms of renal damage and describes new therapeutic approaches to this condition based on novel compounds that target key pathways involved in myoglobin-mediated kidney damage.
横纹肌溶解症是一种由骨骼肌损伤引起的综合征，通常会导致急性肾损伤（AKI）。横纹肌溶解症与多种情况有关，包括严重创伤和剧烈体育锻炼。肌红蛋白诱导的肾毒性通过增加氧化应激、炎症、内皮功能障碍、血管收缩和细胞凋亡，在横纹肌溶解症相关的肾损伤中起关键作用。最近已经开发出针对肌红蛋白有害作用的新药，其中一些已被证明在横纹肌溶解症继发急性肾衰竭的动物模型中取得成功。本综述旨在全面、更新地概述肾损伤的病理机制，并基于针对肌红蛋白介导的肾损伤所涉及关键途径的新型化合物，描述针对这种病症的新治疗方法。
